Tcelltech Secures USD 40 Million Series B Funding for TX-103 CAR-T Therapy Development
China-based Tcelltech Ltd., a developer of T-cell immunotherapies, has reportedly secured close to USD 40...
Tcelltech
Tcelltech’s B7-H3 Targeting CAR-T Therapy TX103 Gets Tacit Clinical Approval for Glioblastoma
The Center for Drug Evaluation (CDE) website in China has indicated that Tcelltech’s TX103, a...